AbbVie Inc. (NYSE:ABBV) Shares Sold by Buckley Wealth Management LLC

Buckley Wealth Management LLC decreased its position in AbbVie Inc. (NYSE:ABBVFree Report) by 17.5% in the second quarter, Holdings Channel reports. The institutional investor owned 16,109 shares of the company’s stock after selling 3,414 shares during the period. AbbVie accounts for about 0.7% of Buckley Wealth Management LLC’s portfolio, making the stock its 27th largest position. Buckley Wealth Management LLC’s holdings in AbbVie were worth $2,170,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Kalos Management Inc. acquired a new position in AbbVie during the first quarter worth $26,000. Boulder Wealth Advisors LLC purchased a new position in shares of AbbVie in the fourth quarter valued at approximately $31,000. Stone House Investment Management LLC purchased a new stake in shares of AbbVie during the first quarter worth approximately $37,000. True Wealth Design LLC purchased a new position in AbbVie in the 4th quarter valued at $39,000. Finally, General Partner Inc. purchased a new stake in shares of AbbVie during the first quarter worth $40,000. 67.86% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on ABBV shares. assumed coverage on shares of AbbVie in a research note on Thursday, August 17th. They set a “strong-buy” rating for the company. Piper Sandler lifted their price objective on AbbVie from $163.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, July 28th. TheStreet raised AbbVie from a “c+” rating to a “b” rating in a research note on Monday, August 28th. HSBC began coverage on shares of AbbVie in a research note on Friday, July 14th. They set a “buy” rating and a $167.00 target price on the stock. Finally, Piper Jaffray Companies increased their price objective on AbbVie from $163.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, July 28th. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from, the company currently has an average rating of “Moderate Buy” and an average price target of $165.79.

View Our Latest Stock Report on ABBV

Insider Transactions at AbbVie

In other AbbVie news, CEO Richard A. Gonzalez sold 18,500 shares of AbbVie stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $149.15, for a total value of $2,759,275.00. Following the sale, the chief executive officer now owns 625,294 shares of the company’s stock, valued at approximately $93,262,600.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.26% of the company’s stock.

AbbVie Price Performance

AbbVie stock opened at $153.93 on Tuesday. The company has a fifty day simple moving average of $146.42 and a 200-day simple moving average of $147.44. AbbVie Inc. has a 12-month low of $130.96 and a 12-month high of $168.11. The company has a current ratio of 0.89, a quick ratio of 0.77 and a debt-to-equity ratio of 4.33. The stock has a market cap of $271.69 billion, a P/E ratio of 31.67, a price-to-earnings-growth ratio of 2.79 and a beta of 0.58.

AbbVie (NYSE:ABBVGet Free Report) last announced its quarterly earnings results on Thursday, July 27th. The company reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.79 by $0.12. AbbVie had a net margin of 15.50% and a return on equity of 151.29%. The firm had revenue of $13.87 billion during the quarter, compared to analysts’ expectations of $13.52 billion. Equities analysts expect that AbbVie Inc. will post 11.03 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be issued a $1.48 dividend. This represents a $5.92 annualized dividend and a dividend yield of 3.85%. The ex-dividend date of this dividend is Thursday, October 12th. AbbVie’s payout ratio is 121.81%.

AbbVie Company Profile

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh├žet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.

Read More

Want to see what other hedge funds are holding ABBV? Visit to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVFree Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with's FREE daily email newsletter.